Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiation Dose De-Escalation with Chemotherapy in HPV-Associated Oropharyngeal Carcinoma
NCT05491512Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2022
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in oropharyngeal carcinoma (OPC) (4 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of participants with any locoregional recurrences at 2 years. Started Aug 2022; status: recruiting.
02
Conditions
oropharyngeal carcinoma (OPC)
Beyond the preview
Go deeper on NCT05491512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05491512.